A Phase I-II study evaluating the feasibility of acute lymphoblastic leukaemia-type intensive consolidation chemotherapy (UKALL XA) after initial C-VAMP and high-dose melphalan auto transplantation at VIIth International Multiple Myeloma Workshop, Stockholm, 2nd September 1999
The implications of compromised renal function at the time of presentation: A single centre study of 251 patients. Annual Meeting of American society of Haematology, New Orleans, December 7 1999.
Light chain disease (LCD): A different form of myeloma compared with IgG disease. Annual Meeting of American society of Haematology, New Orleans, December 7 1999.
High dose chemotherapy and autologous transplantation in myeloma patients aged 65 years and over: A case control comparison with younger patients. Annual Meeting of American society of Haematology, New Orleans, December 7, 1999.
A comparison of kinetics of paraprotein clearance: Rapid decline of paraprotein after high dose melphalan (HDM) versus infusional chemotherapy (IC) in previously untreated patients with IgG multiple myeloma. Annual meeting of EBMT Group, Innsbruck 6h March 2000.
High dose chemotherapy (HDT) and autologous transplantation in myeloma patients aged 65 years and over: A case control comparison with younger patients. Annual meeting of EBMT Group, Innsbruck 6th March 2000.
Glomerular filtration rate (GFR) as a surrogate marker for transplant related toxicity and overall outcome in patients of multiple myeloma (MM) homogenously treated with high dose melphalan (HDM) 200mg/m2. Annual meeting of EBMT Group, Innsbruck 6th March 2000.
Bence-Jones (BJ) Myeloma: A different form of myeloma compared to IgG and IgA myeloma. Annual meeting of EBMT Group, Innsbruck 6th March 2000.
The implication of compromised and normal renal function at presentation in myeloma. Annual meeting of EBMT Group, Innsbruck 6th March 2000.
Kinetics of paraprotein clearance: rapid decline of paraprotein after high-dose melphalan (HDM) compared to infusional chemotherapy in previously untreated patients with IgG myeloma. 5th Annual Meeting of the European Haematology Association. 2000:
Glomerular filtration rate as a surrogate marker for transplant-related toxicity and overall outcome in patients with multiple myeloma homogenously treated with high-dose melphalan. 5th Annual Meeting of the European Haematology Association. 2000:
High-dose therapy and auto transplantation in myeloma patients aged 65 years and over: A case control comparison with younger patients. 5th Annual Meeting of the European Haematology Association. 2000:
Compromised renal function at presentation in myeloma – similar outcome in patients who receive high-dose therapy (HDT): A single centre study of 251 previously untreated patients. British Society of Haematology, Bournemouth, 2000.
Bence Jones (BJ) myeloma: A distinct entity compared to IgG and IgA myeloma. British Society of Haematology, Bournemouth, 2000.
Central nervous system relapses after stem cell transplantation (SCT) for acute leukaemia beyond first remission. British Society of Haematology, Bournemouth, 2000.
Central nervous system relapse after stem cell transplantation for acute leukaemia beyond first remission, Leukaemia 2000; Houston, 6th September 2000
Single centre evaluation of autologous stem cell transplantation in first remission followed by maintenance chemotherapy in patients with acute lymphoblastic leukaemia, Leukaemia 2000; Houston, 6th September 2000
High-dose melphalan and auto transplantation in myeloma patients with severe renal dysfunction (creatinine clearance 20 ml/min/m2): High incidence of atrial fibrillation and treatment-related mortality. Annual Meeting of American society of Haematology, San Francisco, 5th December 2000
Central nervous system relapses in acute leukaemia patients transplanted beyond the first remission. Annual Meeting of American society of Haematology, San Francisco, 5th December 2000
Spectrum of fungal infections in patients with haematological malignancies in the last 5 years: Royal Marsden experience. Annual meeting of EBMT Group, March 2001.
Early response to infusional chemotherapy is an independent prognostic factor in newly diagnosed IgG and IgA multiple myeloma. Annual meeting of EBMT Group, March 2001.
Maximal response to infusional chemotherapy prior to auto transplantation influences outcome of patients with newly-diagnosed multiple myeloma. Annual meeting of EBMT Group, March 2001.
High Dose melphalan and auto transplantation in myeloma patients with severe renal dysfunction: high incidence of atrial fibrillation and treatment-related mortality. Annual meeting of EBMT Group, March 2001.
Role of Defibrotide (Dt) and Therapeutic Plasma Exchange (TPE) in the management of transplant associated thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS): a single centre Experience. Annual meeting of EBMT Group, March 2001.
Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Annual meeting of EBMT Group, March 2001.
High-Dose Melphalan with Autologous Peripheral Stem Cell Rescue in Myeloma Patients with Severe Renal Dysfunction (Creatinine Clearance
<20ml/min/m2): High Incidence of Atrial Fibrillation and Treatment-Related Mortality; British society for Haematology, Harrogate, 23rd April 2001
Early response to infusional chemotherapy is an independent prognostic marker in newly-diagnosed IgG and IgA myeloma, British society for Haematology, Harrogate, 24th April 2001
High-Dose Melphalan with Autologous Peripheral Stem Cell Rescue in Myeloma Patients with Severe Renal Dysfunction (Creatinine Clearance
<20ml/min/m2): High Incidence of Atrial Fibrillation and Treatment-Related Mortality. VIIIth International Myeloma Workshop, Banff, Alberta, Canada, May 6, 2001.
Early Response to Infusional Chemotherapy is an Independent Prognostic Factor in Previously Untreated IgG and IgA Multiple Myeloma. VIIIth International Myeloma Workshop, Banff, Alberta, Canada, May 5, 2001
Rapid early response to infusional chemotherapy is an independent prognostic factor in newly-diagnosed IGG and IGA multiple myeloma, 6th Annual Meeting of the European Haematology Association, Frankfurt, June 2001
The Spectrum of Fungal Infections in Patients with Haematological Malignancies in the Last 5 years: Royal Marsden Experience. 41st ICAAC Meeting, Chicago, 23rd September 2001
Assessment of Maximum tolerated dose of FK463 in cancer patients undergoing HSCT, TIFI, Prague, 18th October 2001
The addition of weekly cyclophosphamide to infusional induction chemotherapy (Vincristine, Doxorubicin, Methylprednisolone) does not affect subsequent stem cell collection in patients with myeloma. Annual Meeting of American society of Haematology, Orlando, 6th December 2001
20-year follow-up of allogeneic bone marrow transplantation with Cyclophosphamide-TBE and Cyclosporine for acute myeloid leukaemia in first complete remission. . Annual Meeting of American society of Haematology, Orlando, 6th December 2001
High-dose melphalan and second autografts for myeloma relapsing after one autograft: Results equivalent to tandem auto transplantation. . Annual Meeting of American society of Haematology, Orlando, 6th December 2001
Early high resolution computed tomography (HRCT) scans allow for prompt diagnosis and more efficacious treatment of invasive pulmonary aspergillosis (IPA) in immunocompromised patients with haematologic malignancies. . Annual Meeting of American society of Haematology, Orlando, 6th December 2001
Hyperleukocytosis in patients with newly diagnosed acute myeloid leukaemia: Clinical implications and consequences of leukapheresis to reduce the tumour burden. . Annual Meeting of American society of Haematology, Orlando, 6th December 2001
Implication of impaired renal function at the time of initiation of infusional chemotherapy (C-VAMP) in patients with newly diagnosed myeloma. . Annual Meeting of American society of Haematology, Orlando, 6th December 2001
The impact of consolidation chemotherapy on the outcome of auto transplantation for acute myeloid leukaemia in first remission: Single-centre experience of 118 adult patients. . Annual Meeting of American society of Haematology, Orlando, 6th December 2001
Outcome of auto transplantation in 118 adult acute myeloid leukaemia patients in first complete remission: impact of consolidation chemotherapy (CC). 28th EBMT Annual Meeting, Montreux, Switzerland. 26th March 2002.
Implications of impaired renal function at the time of initiation of infusional chemotherapy including cyclophosphomide (C-VAMP) in patients with newly diagnosed myeloma. 28th EBMT Annual Meeting, Montreux, Switzerland. 26th March 2002.
Early high-resolution computed tomography (HRCT) scans allow prompt diagnosis and efficacious treatment of invasive pulmonary aspergillosis (IPA) in immunocompromised patients with haematologic malignancies. 28th EBMT Annual Meeting, Montreux, Switzerland. 27th March 2002.
Clinical implications and consequences of leukapheresis to reduce tumour burden in newly diagnosed patients with hyperleukocytosis (HL) and acute myeloid leukaemia. 28th EBMT Annual Meeting, Montreux, Switzerland. 26th March 2002.
Allogeneic transplantation with melphalan-total body irradiation from HLA-identical siblings for AML in first remission: higher relapse rates with marrow-derived stem cell grafts compared to blood despite similar chronic graft-versus-host disease. 28th EBMT Annual Meeting, Montreux, Switzerland. 27th March 2002.
Administration of weekly cyclophosphamide as part of infusional induction chemotherapy (C-VAMP) does not affect subsequent peripheral blood stem cell collection in patients with myeloma. 28th EBMT Annual Meeting, Montreux, Switzerland. 26th March 2002.
20-year follow-up of allogeneic bone marrow transplantation with cyclophosphamide - TBI and cyclosporine for acute myeloid leukaemia in first complete remission. 28th EBMT Annual Meeting, Montreux, Switzerland. 26th March 2002.
Does the Number of Infused CD34 Cells Affect the Long-Term Outcome of Myeloma Patients Treated with High-Dose Melphalan and Auto transplantation? 7th Congress of EHA, 6-9th June 2002, Florence, Italy.
The Addition of Weekly Cyclosphosphamide to Infusional Induction Chemotherapy (Vincristine, Doxorubicin, and Methylprednisolone) Does Not Affect Subsequent Stem Cell Collection in Patients with Myeloma. 7th Congress of EHA, 6-9th June 2002, Florence, Italy.
Bone Marrow or Peripheral Blood Stem Cell Auto transplantation for AML in First Remission? A Matched-Pair Analysis from the Royal Marsden Hospital and the European Blood and Marrow Transplant Group (EBMT). 7th Congress of EHA, 6-9th June 2002, Florence, Italy.
Early high-resolution CT (HRCT) scans allow for prompt diagnosis and efficacious treatment of invasive pulmonary aspergillosis (IPA) in immuno-compromised patients with haematologic malignancies. 7th Congress of EHA, 6-9th June 2002, Florence, Italy.
Implications of impaired renal function at the time of initiation of infusional chemotherapy (C-VAMP) in patients with newly diagnosed myeloma. 7th Congress of EHA, 6-9th June 2002, Florence, Italy.
Clinical implications and consequences of leukapheresis to reduce tumour burden in newly diagnosed patients with hyperleukocytosis (HL) and acute myeloid leukaemia. Annual meeting of British Society of Haematology, Brighton, 2002,
Outcome of auto transplantation in 118 adult acute myeloid leukaemia patients in first complete remission: impact of consolidation chemotherapy (CC). Annual meeting of British Society of Haematology, Brighton, 2002,
Implication of impaired renal function at the time of initiation of infusional chemotherapy including cyclophosphamide (C-VAMP) in patients with newly diagnosed myeloma. Annual meeting of British Society of Haematology, Brighton, 2002,
Relapse following complete remission outcome predictors in patients with secretory myeloma. ). Annual meeting of British Society of Haematology, Brighton, 2002,
Administration of weekly cyclophosphamide as part of infusional induction chemotherapy (C-VAMP) does not affect subsequent peripheral blood stem cell collection in patients with myeloma. ). Annual meeting of British Society of Haematology, Brighton, 2002,
200-mg/m2 Melphalan (HDM200) and Salvage Auto transplantation in Myeloma Patients Relapsing after a Preceding Autograft. Annual meeting of American society of Haematologists, Philadelphia, 9th December 2002.
Adult Patients with De Novo Acute Myeloid Leukaemia Receiving High-Dose Cytarabine-Based Induction Chemotherapy: A Single Centre Study of 136 Patients. Annual meeting of American society of Haematologists, 2003
10-Year Survival in Myeloma: Have the Results Improved in the Last Decade? Annual meeting of American society of Haematologists, 2003
Significance of Length of First Complete Remission (CR) in Newly Diagnosed Secretory Patients with Myeloma: A Study of 131 with a Minimum Follow-Up of 5 Years. Annual meeting of American society of Haematologists, 2003
Primary Refractory (PRef) Myeloma: Recommendations for Treatment. Annual meeting of American society of Haematologists, 2003
Prognostic Significance of Immunoparesis (Ip) at Diagnosis and Continued Complete Remission (CR) in Newly Diagnosed Secretory Myeloma Patients. Session Type: Annual meeting of American society of Haematologists, 2003
Effect of Human Growth Hormone in Haemato-Oncology Patients Receiving Intensive Chemotherapy. A Double Blind Randomized, Placebo-Controlled Study. Annual meeting of American society of Haematologists, 2003
200 mg/m2 Melphalan and Autograft Followed by Maintenance Chemotherapy with 6-Mercaptopurine (6MP), Methotrexate (MTX), and Vincristine-Prednisone (VP) in 65 First Remission Acute Lymphoblastic Leukaemia Patients. Annual meeting of American society of Haematologists, 2003
2 posters at EBMT 2004
Early response to platinum-based chemotherapy in non small cell lung cancer (NSCLC) predicts survival, ASCO 2005
Use of Gemcitabine, Cisplatin and Methylprednisolone (GEM-P) with or without Rituximab in Relapsed and Refractory Patients with Diffuse Large B Cell Lymphoma, ASH 2005.
Retrospective study of Gemcitabine, Cisplatin and Methylprednisolone (GEM-P) with or without Rituximab in Relapsed and Refractory Patients with Diffuse Large B Cell Lymphoma (DLBCL). EBMT 2006
Long-term outcome of high-dose chemotherapy and autologous stem cell transplantation in relapsed/refractory Hodgkin's disease: A cohort of 199 pts from Royal Marsden Hospital, ASCO 2006
The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract, ASCO 2006
The role of maintenance chemotherapy after auto transplantation for acute lymphoblastic leukaemia in first remission: single-centre experience of 100 patients. ASH 2007
Use of platinum-based chemotherapy in patients with triple negative breast cancer, ASCO 2008
Trans-Atlantic Consensus on the Medical Management of Radiation Accident Victims, ASH 2008
Compliance of MAGIC protocol in patients with resectable gastrosophageal (GO) cancer: Tata Memorial Centre (TMC) experience. GI ASCO, San Francisco, 2014
Use of gemcitabine-platinum (Gem-P) in patients with advanced gall bladder (GB) cancer: A more aggressive disease compared to the West—Tata Memorial Centre (TMC) experience. GI ASCO, San Francisco, 2014
Neoadjuvant therapy in Indian patients with locally advanced gall bladder cancer: Tata Memorial Centre (TMC) experience. GI ASCO, San Francisco, 2014
Neoadjuvant therapy in Indian patients with locally advanced gall bladder cancer: Experience from Tata Memorial Centre (TMC), World Congress, IHPBA, Seoul
Neoadjuvant therapy in Indian patients with locally advanced gall bladder cancer: Tata Memorial Centre (TMC) experience. World GI, Barcelona, 2014
Use of Aflibercept as second-line therapy in patients with metastatic colorectal cancer (mCRC) –Named patient program in India. World GI, Barcelona, 2014
Neuropathy post oxaliplatin in Indian patients – no difference between generic and research molecule, World GI, Barcelona, 2014
Treatment of patients with metastatic pancreatic cancer: The Tata Memorial Centre (TMC) experience. World GI, Barcelona, 2014
Treatment of patients with advanced gastric cancer -single centre experience from Tata Memorial Centre (TMC), World GI, Barcelona, 2014